Do women remain at risk even if they do not inherit a familial BRCA1/2 mutation?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Survey of primary care physicians' views about breast and ovarian cancer screening for true BRCA1/2 non-carriers.Journal of community genetics · 2020
   Article
2. Somatic variants of potential clinical significance in the tumors ofHereditary cancer in clinical practice · 2019
   Article
3. Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?PloS one · 2018
   Article
4. No evidence of excessive cancer screening in female noncarriers fromCurrent oncology (Toronto, Ont.) · 2017
   Article

Corrections and comments

• Comment on
  Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry.2011

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as